Stroke and TIA (Transient Ischemic Attack) are the first causes of acquired disabilities in the world.
This video explains what is a stroke, and what can be done to accompany the treatment and rehabilitation of stroke victims.
Since I started my second month I have noticed a significant change I am writing to give you an update on my progress. I have seen changes in my condition during the second month which I want to share with you. Before my taking the treatment I had tremendous spasticity on my my leg but even more in my hand. It was always clenched like a fist and I couldn’t grab anything with it. My ankle also was inverted and this made it hard to walk. My toes also curled under my foot which was very painful. Since I started my second month I have noticed a significant change in my arm. My gross movement is back as well as my coordination and control. The hand is beginning to loosen whereby I can wrap my fingers around a cup or glass. I use my other hand for added support still but my fingers don’t tighten around it now as they used to. It’s not 100% yet but it’s slowly coming back. As far as my leg is concerned I have more strength overall and my sensation is a little bit better, but I haven’t taken off the brace yet. As I get more progress I’ll attempt it down the line. I hope I continue to progress in the third month as well. Thank you very much for your assistance and providing stroke survivors the support they need. Best regards, USA
Her speech has improved and her cognitive thinking is better In reference to Darcy Hewitt stroke disabilities since she had taken the capsules we have seen a lot of improvements. She was severely brain damaged with the stroke. All doctors did not give us much hope for recovery. She is walking and does BM on toilet but her bladder has not caught as of yet hopefully because I trained her and time her for which sometimes good but other days not good. Her speech has improved and her cognitive thinking is better than it was in March 2013 but still needs quite of therapy she is confused but now with directions. She had taken it for almost a year and drank it without any static. I believe NeuroAiD had help her and with time more will repair. Thank You USA
He now understands the most of everything we say and responds accordingly It’s been 3 1/2 months since my father has been taking Neuroaid and I have been seeing progress. He now understands the most of everything we say and responds accordingly. However no speech recovery. He can easily grasp spoon when eating and can hold cup on his own to drink. When he is asked to perform some task such as moving from his bed side onto his wheelchair he would take time and making good use of his thought in analyzing how to do it. The main problem is the right body paralysis . His hand is swollen and painful and his knee cannot be straightened and has drop foot. We will continue to monitor and see his progress in the coming days but relatively everything is going well. Warm regards, UK
He began to engage in small discussions as never before. It was a hilarious moment for the family Dear Michael, As per our discussion regarding my son’s improvement, after the starter pack he began to show signs that has never happened before. His speech changed! he began to engage in small discussions as never before. It was a hilarious moment for the family. His movements in the limbs got a lot better too. A big Thanks to Neuroaid Team especially Michael who had shown much concern on this especially with the way of encouragement and direction. Kind regards, Nigeria
Stroke is the first cause of acquired disability in the world
A stroke, brain attack, or a Cerebrovascular Accident (CVA), is the sudden death of brain cells caused by a lack of supply in oxygen to the brain.
There are two main types of stroke:
Ischemic strokes or cerebral infarcts: 80% of strokes result from a blockage or a reduction of blood flow in an artery that irrigates the brain. They are caused either by a blood clot (thrombus) which blocks the blood vessel or by the buildup of plaque (often due to cholesterol) within the arteries which narrows vessels resulting in a loss of blood flow.
Haemorrhagic strokes: 20% of strokes, due to the rupture of an artery within the brain triggering an intracerebral haemorrhage (15% of strokes) or to the rupture of an aneurysm (arteriovenous malformation) entailing subarachnoid haemorrhage (5% of strokes).
What are the consequences of a stroke?
Resulting disabilities will vary depending on stroke location and severity.
After a stroke, brain cells die in the affected areas resulting to damaged or even lose neurons. Patients will often suffer physical disabilities such as partial loss of motricity or hemiplegia, sensory loss, language disorders, aphasia, visual disorders, and even memory loss.
Level of recovery will vary from patient to patient.
Starting rapidly a rehabilitation program is key to recovery.
Is there anything to boost recovery?
NeuroAiD™ is a recovery stimulator
dedicated to support neurological functions*.
NeuroAiD™ recovery stimulator has been shown to increase the production of new neurons in the brain and supports the formation of new connections. The effects of this favorable brain environment have been shown to improve the outcome of recovery in clinical trials: patients on NeuroAiD™ have a 2.4 times higher chance of reaching independence**.
* This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent disease. ** Clinical study published in peer reviewed journal “Stroke”. Reference: Stroke. 2009 Mar;40(3):859-63.
How does NeuroAiD™ work?
NeuroAiD™ creates a favorable environment to enhance neuroplasticity.
Precisely, NeuroAiD™ triggers the production of new neurons in our brain (neurogenesis) and favors connections between neurons by stimulating the formation of dendrites and synapses (neuroplasticity).
This favors the formation of new functional neuronal circuits, which are key to a fuller post-stroke recovery. The changes in the brain materialize into more progress in neurological functions during rehabilitation. This neurorehabilitative activity of NeuroAiD™ was established in 2010 by a team of French scientists and published in peer reviewed international journal.
Is NeuroAiD clinically proven?
NeuroAiD™ Improves Functional Outcome
NeuroAiD™ improves odds of achieving independence by 63% in post-acute stage*
*Post-acute phase defined as >48hours when patients no longer require urgent interventions and intensive monitoring
Benefits observed as early as 3 months
A review of all clinical trials assessing the benefits of NeuroAiD™ in recovering independence was published in 2013. I It showed that NeuroAiD™ increases by 63% the chances of being independent and noted a trend towards more improvement in movement. Independence for a stroke victim is defined as being able to take care of oneself and speak freely.
Benefits persisting over time
The CHIMES Study Extension (CHIMES-E) provides encouraging results in achieving functional independence over the long term with a follow-up of 24 months after stroke onset of the patients included in CHIMES (recruited and initiated a 3-month course of NeuroAiD™ vs Placebo with 72 hours of ischemic stroke onset). An initial 3-month course with NeuroAiD™ significantly increases odds of achieving functional independence after a stroke at 6 months in overall population and these benefits are persisting over time.
Improving Motor Recovery
A study of 150 subjects recruited between 1 week and 3 months after stroke onset received 3 months of treatment. Motor recovery was assessed by Fugl-Meyer motor assessment scale (maximum score 100 points) every month for 3 months. This study showed that the motor recovery of patients on NeuroAiD™ was significantly much more than patients on placebo, and this difference was seen as early as 4 weeks from start of treatment and persists up to 3 months.
Reducing early recurrence of stroke, heart attack and deaths by 50% after a stroke
A study was performed to investigate the effect of NeuroAiD™ on the occurrence of early vascular events, defined as a composite of recurrent stroke, acute coronary syndrome, and vascular death within 3 months after stroke onset. A statistically significant reduction in the risk of vascular events and/or vascular death by half was observed in the first three months after a stroke: occurred in 47 (4.3%) patients over the 3-month follow-up period, with 16 (2.9%) patients in the NeuroAiD™ group and 31 (5.6%) in the placebo group. It corresponds to 27 patients avoiding the occurrence of early vascular events per 1000 patients treated for 3 months. The benefit is in addition to the benefits gained from secondary prevention standard treatment. The reduction was seen as early as the first two weeks after initiation of treatment. There was no increase in bleeding and non-vascular death, confirming the excellent safety profile of NeuroAiD ™. This finding is consistent with the pleotropic mechanisms of action of NeuroAiD™ including its effect on ATP-sensitive potassium channel and its potential role in ischemic preconditioning.